Biotech Essentials

Startups

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech Essentials

Top news of the week: 01.09.2021.

#IgniteGoldenTicket
#GoodDayBIO
#drugtherapy
#funding
#GI
#neuro
#gastrointestinal
#eRNA
#biotech
#drugprice

Startups

@MassBio shared
On Aug 27, 2021
With support from @abbvie, @IgniteLC is awarding Ignite Golden Tickets to biotech start-ups with founders from underrepresented groups. The winning companies will get 1 bench for 1 scientist for 1 year at @labcentral! What are you waiting for? APPLY NOW! https://t.co/hA3aZzEtd4 https://t.co/ydjaAzqBt5
Open
LabCentral Ignite Golden Tickets

LabCentral Ignite Golden Tickets

WHAT is a LabCentral Ignite Golden Ticket? cover the cost of one bench and one scientist for one year at LabCentral and include exclusive access to our network and resources as a …

@big4bio shared
On Aug 30, 2021
Neurogastrx convinced investors to put $60M into getting two of the company's leading candidates, a late-stage acid reflux drug and another mid-stage #gastrointestinal treatment, out into the world. #funding #neuro #GI #drugtherapy Read more here: https://t.co/yd4Dp67IH0
Open
Neurogastrx assembles ex-Ironwood team with $60M to take on jam-packed gastrointestinal market

Neurogastrx assembles ex-Ironwood team with $60M to take on jam-packed gastrointestinal market

Neurogastrx is attempting to go up against a long-standing class of GERD drugs and others in the gastrointestinal disorder space. The biotech now has $60 million to bankroll a phase 3 study ...

@BusinessInsider shared
On Aug 29, 2021
RT @thisisinsider: 'Hillbilly Elegy' author JD Vance is running for Senate as a savior of the Rust Belt. Insiders and experts say otherwise. https://t.co/LnkxIcy15X
Open
'Hillbilly Elegy' author JD Vance is running for Senate as a savior of the Rust Belt. Insiders and experts say otherwise.

'Hillbilly Elegy' author JD Vance is running for Senate as a savior of the Rust Belt. Insiders and experts say otherwise.

J.D. Vance, of "Hillbilly Elegy," is promoting his business acumen in a crowded Senate primary. But Insider found a record that's mixed at best.

@BusinessInsider shared
On Aug 30, 2021
RT @FinanceInsider: Meet 5 Blackstone life-sciences dealmakers powering a $4 billion investing spree in groundbreaking treatments https://t.co/9uSYi2uEsd
Open
Meet 5 Blackstone life-sciences dealmakers powering a $4 billion investing spree in groundbreaking treatments

Meet 5 Blackstone life-sciences dealmakers powering a $4 billion investing spree in groundbreaking treatments

Blackstone's life-sciences team brings therapies to market, having invested $4 billion in cutting-edge tech like COVID vaccines and medical supplies.

@big4bio shared
On Aug 31, 2021
RT @big4bioBOS: .@endlessRNA (Laronde) raised $40M in a Series B #financing to advance the development of its platform for #eRNA, an engineered form of RNA that can be progressed to express therapeutic proteins, and a broad pipeline of programs. #biotech Read more here: https://t.co/msMOU48u5J
Open
As RNA remains hot, Flagship’s Laronde raises $440m for a new class of medicines

As RNA remains hot, Flagship’s Laronde raises $440m for a new class of medicines

Laronde is based on a proprietary molecule its scientists call “endless RNA,” which the company hopes will allow humans to produce their own proteins for weeks or months to treat diseases.

@BusinessInsider shared
On Aug 28, 2021
Opinion | I'm a tech executive who moved from Silicon Valley to Houston. I know firsthand why the tech industry is packing up and heading to Texas. By Yang Tang. https://t.co/HqdUc9TCT3
Open
I'm a tech executive who moved from Silicon Valley to Houston. I know firsthand why the tech industry is packing up and hightailing it to Texas.

I'm a tech executive who moved from Silicon Valley to Houston. I know firsthand why the tech industry is packing up and hightailing it to Texas.

There is a reason tech companies are relocating to Texas and billions of dollars of venture capital money is being poured into the state.

@FierceBiotech shared
On Aug 31, 2021
Novartis previously culled the drug after it didn't pass muster in a phase 2b/3 study for sporadic inclusion body myositis, a rare, muscle-wasting disease https://t.co/THlvZCVPm3
Open
Versanis Bio snags $70M for a ditched Novartis muscle drug, with a little help from its old CEO Joe Jimenez

Versanis Bio snags $70M for a ditched Novartis muscle drug, with a little help from its old CEO Joe Jimenez

Versanis Bio emerged with a $70 million series A to test a former failed Novartis drug in a phase 2 study for obesity. Backing the biotech is former Novartis CEO Joe Jimenez, who was in the ...

@IAmBiotech shared
On Aug 31, 2021
#GoodDayBIO: A reminder of the importance of a #OneHealth approach to public health. Plus, biotech leaders from Delaware, New Jersey, and Pennsylvania explain the impact #drugprice controls would have on jobs and innovation in their states. https://t.co/VletONZu1f
Open
Good Day BIO: Sick pigs and melting glaciers

Good Day BIO: Sick pigs and melting glaciers

What do sick pigs and melting glaciers have in common? We tell you below. Plus, biotech leaders from Delaware, New Jersey, and Pennsylvania explain the impact drug price controls would have ...

Read more: Startups
weekly 01.09.2021
View archives
Back to home

Subscribe to Biotech Essentials - Startups.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech Essentials - Startups.
Privacy Policy

Sign up for the weekly Biotech Essentials - Startups newsletter

Never again miss anything or anyone that matter in Biotech Essentials

Sign up and receive the Biotech Essentials - Startups weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy